- Home
- AVT vs RYTM Comparison
AVT vs RYTM Comparison
Compare AVT & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVT
- RYTM
- Stock Information
- Founded
- AVT 1921
- RYTM 2008
- Country
- AVT United States
- RYTM United States
- Employees
- AVT N/A
- RYTM N/A
- Industry
- AVT Electronic Components
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- AVT Technology
- RYTM Health Care
- Exchange
- AVT Nasdaq
- RYTM Nasdaq
- Market Cap
- AVT 4.4B
- RYTM 3.8B
- IPO Year
- AVT N/A
- RYTM 2017
- Fundamental
- Price
- AVT $50.42
- RYTM $57.38
- Analyst Decision
- AVT Sell
- RYTM Strong Buy
- Analyst Count
- AVT 4
- RYTM 12
- Target Price
- AVT $49.00
- RYTM $75.42
- AVG Volume (30 Days)
- AVT 955.8K
- RYTM 671.0K
- Earning Date
- AVT 04-30-2025
- RYTM 05-07-2025
- Dividend Yield
- AVT 2.61%
- RYTM N/A
- EPS Growth
- AVT N/A
- RYTM N/A
- EPS
- AVT 3.56
- RYTM N/A
- Revenue
- AVT $22,145,935,000.00
- RYTM $136,863,000.00
- Revenue This Year
- AVT N/A
- RYTM $43.84
- Revenue Next Year
- AVT $6.28
- RYTM $65.62
- P/E Ratio
- AVT $14.22
- RYTM N/A
- Revenue Growth
- AVT N/A
- RYTM 48.88
- 52 Week Low
- AVT $39.22
- RYTM $35.17
- 52 Week High
- AVT $59.24
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- AVT 55.91
- RYTM 43.00
- Support Level
- AVT $48.77
- RYTM $62.69
- Resistance Level
- AVT $50.41
- RYTM $65.53
- Average True Range (ATR)
- AVT 1.48
- RYTM 3.04
- MACD
- AVT 0.13
- RYTM -0.73
- Stochastic Oscillator
- AVT 66.38
- RYTM 1.14
About AVT Avnet Inc.
Avnet Inc is a global distributor of electronic components, connecting suppliers of semiconductors and other components to a base of 2.1 million small- and mid-sized customers in 140 countries. Avnet is the third largest semiconductor distributor in the world, and the largest for European chip distribution. Avnet services all levels of electronics design and development, servicing engineers with design tools, test kits, and services alongside its high-volume distribution for final designs.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.